Our world-class neurology research and development organisation is pushing towards novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease.
We view Alzheimer’s disease as an area where we can make a significant difference in the lives of patients. There are currently no treatments to prevent, delay or stop disease progression.
Alzheimer’s disease is a progressive neurological condition that impairs the thinking and independence of millions of people worldwide.1 More than half a million people in the United Kingdom are living with Alzheimer’s disease, with these numbers growing rapidly.2
This disease destroys not only quality of life but also quantity – it is a leading cause of mortality.
Alzheimer’s disease is usually diagnosed in people 65 and older, but it starts earlier with subtle neurological changes occurring years or even decades before symptoms appear.2
Biogen has made a long-term commitment to furthering Alzheimer’s disease research and treatment. Our vision is to redefine Alzheimer’s disease through innovative medicines to improve the lives of patients and their caregivers.
With an emphasis on early-stage disease, our research programmes target several of the identified causes, amyloid and tau pathology – proteins believed to play a critical role in Alzheimer’s disease development. These programmes range from preclinical to phase 3 clinical trials.
Learn more about our investigational therapies.
1. World Health Organization. Dementia. Available at: www.who.int/news-room/fact-sheets/detail/dementia. Last Accessed, September 2018.
2. Alzheimer’s Society. Who gets Alzheimer's disease? Available at: www.alzheimers.org.uk/about-dementia/types-dementia/who-gets-alzheimers-disease#content-start. Last accessed, September 2018.
BI-IRL-0329 Date of preparation: October 2018